{
    "nct_id": "NCT04583033",
    "title": "Lifestyle Stressors of Hippocampus and Alzheimer's Disease (AD) Related Brain Regions: Potential for Intervention",
    "status": "COMPLETED",
    "last_update_time": "2023-11-29",
    "description_brief": "The purpose of this study is to slow down the aging of the participant's brain by improving sleep quality.",
    "description_detailed": "N/A",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "PREVENTION",
    "results": null,
    "target_category": "N/A",
    "drug": [],
    "placebo": [],
    "explanation_target": [
        "Reason: The study title and purpose indicate a behavioral/lifestyle intervention aiming to slow brain aging by improving sleep quality (i.e., modify sleep to affect hippocampus/AD-related regions). This is not a biologic (monoclonal antibody or vaccine) nor a small-molecule drug, and it is not a drug-based cognitive enhancer or a neuropsychiatric-symptom drug trial. The trial description explicitly lists a behavioral intervention (Cognitive Behavioral Therapy). \ue200cite\ue202turn0search6\ue201",
        "Act: Key extracted details from the trial registry \u2014 Title: \"Lifestyle Stressors of Hippocampus and Alzheimer's Disease (AD) Related Brain Regions: Potential for Intervention\"; Purpose: \"to slow down the aging of the participant's brain by improving sleep quality\"; Intervention type listed: Behavioral \u2014 Cognitive Behavioral Therapy (CBT); Enrollment: 100; Location: University of Miami, FL. There is no investigational drug or placebo specified in the registry entry. \ue200cite\ue202turn0search6\ue201",
        "Act (supporting literature): Sleep disruption is linked to AD-related pathology and cognition (mechanistic and observational evidence that poor sleep associates with greater amyloid burden and may affect hippocampal function), which justifies sleep-targeting interventions for AD risk \u2014 example systematic review/meta-analysis and mechanistic review. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Act (context): Pharmacologic sleep interventions have been tested in other AD-related trials (e.g., trazodone trials aiming to improve slow-wave sleep and cognition), but that is different from this trial which uses behavioral CBT rather than a drug. \ue200cite\ue202turn0search1\ue201",
        "Reflect: Given the intervention is behavioral (CBT to improve sleep) and no drug or biologic is being tested, the trial does not fit the four provided drug/biologic/symptom categories. Although improving sleep may have downstream cognitive or disease-modifying effects, the provided category list is limited to drug/biologic/cognitive-enhancer/neuropsychiatric drug categories; therefore the correct classification is 'N/A'. The trial registry and supporting literature cited above back this interpretation. \ue200cite\ue202turn0search6\ue202turn0search5\ue201"
    ],
    "agent_type": "N/A",
    "explanation_agent": []
}